We have extensive experience in the synthesis of Proteolysis Targeting Chimeras (PROTAC) and partial PROTAC, including the development and functionalization of various E3-ligase ligands such as CRBN, VHL, MDM2 ,and cIAP1, some of them even in multi-gram scale. In addition to the synthesis of commercially available ligands, we are also experienced in developing novel structural analogues.
We also synthesize a large variety of linkers needed for the linkage of E3-Ligase ligands to the target-binding ligands, including PEG linkers, carbon-based chains, with a large variety of end functionalities including –NH2, –CO2H, –N3, –C≡CH, –CHO, –X and –OH to be connected with almost any active targets.
We have unique capabilities for tailor-made partial PROTACs, which are ready for rapid target linkage. We also have a series of E3-ligase ligands and linkers on our shelves.
Our in-house collection offers clients a quick and efficient way to jump-start their drug discovery programs and reach meaningful conclusions faster.
We complement our medicinal chemistry of PROTACs with a vast experience in the biology of protein degraders and comprehensive in vitro biology support, including various biological assays, DMPK and toxicology support.
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.